Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss,Diabetes, Obesity and Metabolism

当前位置： X-MOL 学术 › Diabetes Obes. Metab. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2021-09-13 , DOI: 10.1111/dom.14551
Sean Wharton ₁ , Salvatore Calanna ₂ , Melanie Davies _{3,

4} , Dror Dicker ₅ , Bryan Goldman ₂ , Ildiko Lingvay ₆ , Ofri Mosenzon ₇ , Domenica M. Rubino ₈ , Mette Thomsen ₂ , Thomas A. Wadden ₉ , Sue D. Pedersen ₁₀

Affiliation

York University, McMaster University and Wharton Weight Management Clinic Toronto Ontario Canada
Novo Nordisk A/S Søborg Denmark
Diabetes Research Centre University of Leicester Leicester UK
NIHR Leicester Biomedical Research Centre Leicester UK
Internal Medicine Department & Obesity Clinic, Hasharon Hospital‐Rabin Medical Center Petach‐Tikva, Sackler Faculty of Medicine, Tel Aviv University Tel Aviv Israel
Departments of Internal Medicine/Endocrinology and Population and Data Sciences University of Texas Southwestern Medical Center Dallas TX USA
Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center; Faculty of Medicine Hebrew University of Jerusalem Israel
Washington Center for Weight Management and Research Arlington VA USA
Department of Psychiatry, Perelman School of Medicine University of Pennsylvania Philadelphia PA USA
C‐ENDO Diabetes & Endocrinology Clinic Calgary Calgary AB Canada

We evaluated gastrointestinal (GI) adverse events (AEs) with once-weekly semaglutide 2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL).

中文翻译：